Cargando…
Experimental Nuclear Medicine Meets Tumor Biology
Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence o...
Autores principales: | Balber, Theresa, Tran, Loan, Benčurová, Katarína, Raitanen, Julia, Egger, Gerda, Mitterhauser, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878163/ https://www.ncbi.nlm.nih.gov/pubmed/35215337 http://dx.doi.org/10.3390/ph15020227 |
Ejemplares similares
-
CAM-Xenograft Model Provides Preclinical Evidence for the Applicability of [(68)Ga]Ga-Pentixafor in CRC Imaging
por: Benčurová, Katarína, et al.
Publicado: (2022) -
In vitro Radiopharmaceutical Evidence for MCHR1 Binding Sites in Murine Brown Adipocytes
por: Balber, Theresa, et al.
Publicado: (2019) -
Comparison of Radiation Response between 2D and 3D Cell Culture Models of Different Human Cancer Cell Lines
por: Raitanen, Julia, et al.
Publicado: (2023) -
Sorbitol as a Polar Pharmacological Modifier to Enhance the Hydrophilicity of (99m)Tc-Tricarbonyl-Based Radiopharmaceuticals
por: Giammei, Carolina, et al.
Publicado: (2020) -
Synthesis and Preclinical Evaluation of Radiolabeled [(103)Ru]BOLD-100
por: Happl, Barbara, et al.
Publicado: (2023)